An organic amine ester derivative drug of 2-(-hydroxypentyl)benzoic acid and a preparation method thereof and an use thereof are disclosed. The present disclosure particularly relates to a compound having the general formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable formulation prepared from the compound or the pharmaceutically acceptable salt thereof. The compound having the general formula I or the pharmaceutically acceptable salt thereof has in vitro a good solubility and a low hygroscopicity, and has in vivo a bioavailability and a brain aggregation concentration that are significantly greater than those of the original medicine butyphthalide and/or an improving drug efficacy. The use of the compound in the preparation of a drug for preventing and/or treating heart and cerebral ischemic diseases, a drug for preventing and/or treating heart and cerebral artery occlusion diseases, an anti-parkinsonian drug and an anti-senile-dementia drug is also disclosed.

##STR00001##

A disclosed are an acetylsalicylic acid derivative, i.e. a 2-(diethylamino)ethyl 2-acetoxy-benzoate hydrochloride crystal, and a preparation method and use thereof. The X-ray powder diffraction (XRPD) pattern of the crystal has characteristic peaks at the following 2 angle: 11.00.2, 20.60.2, 25.10.2, 8.20.2, 16.50.2, 13.40.2, 25.40.2. ##STR00001##

A disclosed are an acetylsalicylic acid derivative, i.e. a 2-(diethylamino)ethyl 2-acetoxy-benzoate hydrochloride crystal, and a preparation method and use thereof. The X-ray powder diffraction (XRPD) pattern of the crystal has characteristic peaks at the following 2 angle: 11.00.2, 20.60.2, 25.10.2, 8.20.2, 16.50.2, 13.40.2, 25.40.2. ##STR00001##

A disclosed are an acetylsalicylic acid derivative, i.e. a 2-(diethylamino)ethyl 2-acetoxy-benzoate hydrochloride crystal, and a preparation method and use thereof. The X-ray powder diffraction (XRPD) pattern of the crystal has characteristic peaks at the following 2 angle: 11.00.2, 20.60.2, 25.10.2, 8.20.2, 16.50.2, 13.40.2, 25.40.2.

##STR00001##

A disclosed are an acetylsalicylic acid derivative, i.e. a 2-(diethylamino)ethyl 2-acetoxy-benzoate hydrochloride crystal, and a preparation method and use thereof. The X-ray powder diffraction (XRPD) pattern of the crystal has characteristic peaks at the following 2 angle: 11.00.2, 20.60.2, 25.10.2, 8.20.2, 16.50.2, 13.40.2, 25.40.2.

##STR00001##

It is provided herein a benzobicycloalkane derivative, and a preparation method and use thereof. In particular, it is provided herein a compound of Formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method, and a use thereof in preparation of drugs for treating pain. ##STR00001##

A resist composition comprising a base polymer and a quencher in the form of an amine compound having an iodized aromatic ring bonded to the nitrogen atom via a divalent hydrocarbon group offers a high sensitivity and minimal LWR or improved CDU, independent of whether it is of positive or negative tone.

Disclosed are an acetylsalicylic acid derivative, i.e. a 2-(diethylamino)ethyl 2-acetoxy-benzoate hydrochloride crystal, and a preparation method and use thereof. The X-ray powder diffraction (XRPD) pattern of the crystal has characteristic peaks at the following 2 angle: 11.00.2, 20.60.2, 25.10.2, 8.20.2, 16.50.2, 13.40.2, 25.40.2. ##STR00001##

Disclosed are an acetylsalicylic acid derivative, i.e. a 2-(diethylamino)ethyl 2-acetoxy-benzoate hydrochloride crystal, and a preparation method and use thereof. The X-ray powder diffraction (XRPD) pattern of the crystal has characteristic peaks at the following 2 angle: 11.00.2, 20.60.2, 25.10.2, 8.20.2, 16.50.2, 13.40.2, 25.40.2. ##STR00001##

Disclosed are benzoate derivatives. Provided is a compound having a formula selected from the group consisting of following structures. The compound can be used for quality control over a 2-(diethylamino)ethyl 2-acetoxybenzoate hydrochloride product, and also for inflammation diminishment.

##STR00001##